Phase III
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 24, 2020.
According to a report, three people briefed on the plan indicated Trump wants to give AstraZeneca and the University of Oxford’s experimental COVID-19 vaccine emergency use authorization ahead of the U.S. presidential election on November 3.
It was a relatively quiet week for clinical trial news. Here’s a look.
Following approval of its coronavirus vaccine, the first in the world, Russia plans to initiate a new study involving 40,000 people as the country looks to boost production and distribute the drug to patients in that country, as well as to patients in countries it has struck deals with.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 21, 2020.
“We are grateful to the NIA for their rigorous scientific review and funding support to advance ALZ-8801 for Alzheimer’s patients in need of an effective treatment,” said Martin Tolar, founder, president and chief executive officer of Alzheon.
Despite the urgent need for more research into the coronavirus, the New York Times reported on August 14 that there have been numerous testing delays, staffing shortages and space constraints tying up the process.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 19, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 17, 2020.
Phase III clinical trials for Russia’s Sputnik V vaccine for COVID-19 began Wednesday, one day after the Russia Direct Investment Fund (RDIF) launched a new website to share the details of the vaccine with the public and scientists around the world.
PRESS RELEASES